Andrea Small Howard

GB Sciences, Inc./ GbS Global Biopharma, Inc, United States

Title: Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson’s disease

---

Biography

Dr. Small-Howard leverages her broad biopharmaceutical industry knowledge as the President, Chief Science Officer, and member of the Board of Directors at both GB Sciences, Inc. (OTCQB:GBLX), and their wholly-owned Canadian subsidiary, GBS Global Biopharma, Inc. Dr. Small-Howard brings her passion for advancing research on phytochemical compounds to her current roles. She envisages bringing more phytomedicines to market through an innovative AI-based drug discovery engine and biopharmaceutical drug development program for disease-specific indications.

Dr. Small-Howard has researched cannabinoids for over 20 years, leading a project group dedicated to the study of cannabinoids in the immune system as an NIH-funded post-doctoral fellow. In this work she published one of the earliest studies of cannabinoid impacts on pro-inflammatory immunocytes. More recently she has contributed to published studies on consumer protection issues surrounding ‘medicinal’ Cannabis chemovars in Nevada, co-authored scholarly reviews on cannabinoids in heart disease and Parkinson’s Disease, co-authored mechanistic studies on cannabinoid and terpene regulation of ion channels, and co-authored an innovative study demonstrating the utility of nanoparticles as delivery vehicles for Cannabis-derived therapeutic compounds.

Abstract

Neuroscience, 

Parkinson’s Disorders